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Excitation-coupled Ca2+ entry (ECCE)CaV1.1 is the prototype for the other nine known CaV channel isoforms, yet it has functional properties that
make it truly atypical of this group. Speciﬁcally, CaV1.1 is expressed solely in skeletal muscle where it serves
multiple purposes; it is the voltage sensor for excitation–contraction coupling and it is an L-type Ca2+ channel
which contributes to a form of activity-dependent Ca2+ entry that has been termed Excitation-coupled Ca2+
entry. The ability of CaV1.1 to serve as voltage-sensor for excitation–contraction coupling appears to be unique
among CaV channels, whereas the physiological role of its more conventional function as a Ca2+ channel has
been a matter of uncertainty for nearly 50 years. In this chapter, we discuss how CaV1.1 supports excitation–
contraction coupling, the possible relevance of Ca2+ entry through CaV1.1 and how alterations of CaV1.1 function
can have pathophysiological consequences. This article is part of a Special Issue entitled: Calcium channels.
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CaV1.1 is the prototypical voltage-gated Ca2+ channel. Like the
other L-type (CaV1.X) Ca2+ channels, it is deﬁned by its being respon-
sive to inhibition or potentiation by 1,4-dihydropyridines. It was them channels.
+1 303 724 4501.
A. Bannister),
rights reserved.ﬁrst member of the CaV family to be cloned [1] and it was the ﬁrst
ion channel to have a null mouse model [2]. Yet CaV1.1 is so atypical
of the CaV family, one could say that it is the unicorn of the family.
Compared to the other nine CaV channels, it activates slowly and inac-
tivates even more slowly. Its expression is restricted to one tissue—
skeletal muscle—where it is the only CaV channel expressed in differ-
entiated ﬁbers. Moreover, CaV1.1 requires the inﬂuence of the type 1
ryanodine receptor (RyR1) to support its L-type channel function. How-
ever, the physiological signiﬁcance of L-type Ca2+ current via CaV1.1 is
uncertain [3,4], and the ability of CaV1.1 to carry out its most important
function does not depend on Ca2+ ﬂux at all [5,6].
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As noted above,α1S (CaV1.1) was the ﬁrst principal α1 subunit of a
CaV channel for which a complete cDNA sequence was obtained,
which like the initial cloning of many other ion channels was accom-
plished by the Numa laboratory in the 1980s [1]. Their work made use
of rabbit skeletal muscle, which abundantly expresses receptors for
1,4-dihydropyridine receptors (DHPRs), although it must be noted that
the equivalence of DHPRs and voltage-gated Ca2+ channels was at the
time a source of much debate [7,8]. In any event, sequencing of tryptic
fragments of puriﬁed DHPRswas used to design oligonucleotide primers
for reverse transcription of muscle mRNA. From the resulting cDNA se-
quence, they concluded that the basic structure was much like the ﬁrst
rat brain Na+ channel (now known as NaV1.1) which they had cloned
just prior [9]. Like NaV1.1, the α1S subunit of the channel had four re-
peats, having sequence similarity with one another (Fig. 1). The amino-
and carboxyl-termini, as well as the loops linking the four repeats
(I–II, II–III, III–IV)were proposed to be cytoplasmic. These cytoplasmic re-
gions are nowknown to be important for interactionswith other proteins
and play roles in gating, expression and targeting of CaV1.1 (reviewed in
[10]). Eachof the four repeats is comprised of sixα-helices, and the fourth
helix (S4) of each repeat has a distinctive motif of evenly spaced basic
residues which correspond to the voltage-sensing particle that Hodgkin
and Huxley had proposed thirty years earlier for neuronal Na+ channels
[11]. Importantly, the channel differed from NaV1.1 in that the residues
that corresponded to the Na+ channels' D-E-K-A selectivity ﬁlter were
E-E-E-E [12,13]. This tetra-acidic structure was postulated to facilitate se-
lective passage of Ca2+ and other divalent cations such as Ba2+, Mg2+,
Mn2+and Sr2+ through the pore of L-type channels byproviding binding
sites for two separate divalents [14]. To this day, thismotif is known to be
important for the selectivity of CaV1.1; neutralization of just one of these
residues in the third conserved repeat will nearly ablate the ability of theCaV1
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Fig. 1. Schematic representation of the CaV1.1. Cartoon illustrating the membrane topology
single polypeptide composed of four relatively conserved repeats (I, II, II and IV) containing
of basic residues that is believed to be critical for voltage-sensing. The segments linking the
the site of interaction with the predominantly intracellular β1a subunit (illustrated). The red
coupling (residues 720–765) [59]. The black box within the blue box represents the “A d
carboxyl-terminal domain [65]. The carboxyl terminus contains a proteolytic cleavage site at
of CaV1.1 to couple to RyR1 [168]. The yellow segment indicates the position of an alternative
indicate known hypokalemic periodic paralysis (R528H, R900H and R1239H; please see tex
been linked to malignant hyperthermia susceptibility (R174W, R1086H/C/S and T1354S; pleaschannel to conduct divalents and will convert it into a Na+-selective
channel [5,15–17].
3. CaV1.1 is assembled as heteromultimer together with α2δ-1, β1a
and γ1 subunits
The skeletal muscle L-type Ca2+ channel is comprised of CaV1.1 and
auxiliary α2δ-1, β1a, and γ1 subunits. With the exception of α2δ-1, ex-
pression of each of these subunit isoforms is largely restricted to skeletal
muscle ([18,19], but see [20]). Ablation of eitherα2δ-1 or γ1 expression
has only modest effects on channel current density [21–26]; the main
effect of α2δ-1 is to slow activation kinetics [24–26] and that of γ1 is
to cause a depolarizing shift of channel inactivation [21–23], but the
broader physiological signiﬁcance of these effects is not clear. On the
other hand, β1a is nearly essential for channel function [27,28]. Like
CaVβ subunit isoforms in other tissues, the β1a subunit facilitates traf-
ﬁcking of CaV1.1 to the plasma membrane. However, the speciﬁc
targeting of the assembled CaV1.1 channel complex to the junctional
membrane is dependent on CaV1.1 [29–31]. Within the junctional
membrane, individual CaV1.1-containing heteromultimers are arranged
into groups of four (“tetrads”), in which the four CaV1.1 channels are
aligned with the four subunits of every other RyR1 homotetramer
(Fig. 2—left) [30,32–38]. By itself, the highly-registered tetradic organiza-
tion of CaV1.1 at triad junctions is perhaps the most concrete evidence of
physical interactions linking CaV1.1 to RyR1. This view is fortiﬁed by the
observations that long duration pharmacological manipulation of RyR1
conformationwith high concentrations of ryanodine (>200 μM) reduces
the average, center-to-center distance between adjacent DHPRs within a
tetrad [38] and shifts activation of both L-type current [39,40] charge
movement [40] to more hyperpolarized test potentials.
In addition to promoting trafﬁcking of the CaV1.1 complex to the
membrane,β1a is essential for efﬁcient tetrad formation. Triad junctions.1
III IV
799
main C-terminal domain
(highly conserved)
Exon 29
C
765
of CaV1.1. Like NaV channels and the other nine members of the CaV family, CaV1.1 is a
six α-helices apiece. The fourth α-helix of each repeat has a regularly spaced sequence
repeats, as well as the amino- and carboxyl-termini, are intracellular. The I–II-linker is
box in the II–III loop represents the “critical domain”which is essential for engaging EC
omain” (residues 681–690) [66,68]. The green box represents the highly conserved
residue A1664 (hatch) [167], although this cleavage does not appear to affect the ability
splice (exon 29) in the extracellular S3–S4 linker of Repeat IV [158]. The red explosions
t for references) mutations and the yellow stars signify residue substitutions that have
e see text for references).
+ 1a - 1aβ β
Fig. 2. Tetradic organization of CaV1.1 channels at plasma membrane junctions requires the CaVβ1a subunit. Electron micrographs of freeze-fracture replicas of zebraﬁsh membrane
junctions are shown in both panels. In wild-type muscle (left), CaV1.1-containing channels exist in tetrads aligned with the four subunits of every other RyR1 homotetramer; each
tetrad is highlighted by a red dot. In relaxed, or β1 null, muscle, the CaV1.1 particles are sparse and tetrads are absent (right).
Figure modiﬁed from Schredelseker et al. [30] with permission from the publisher; ©The Proceedings of the National Academy of Sciences of the USA, 2005.
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CaV1.1 particles in freeze-fracture replicas (Fig. 2—right); transgenic
overexpression of β1a in relaxed embryos restores the orthogonal CaV1.1
tetradic arrays [30]. The rescue of tetrads is an exclusive function of β1a
[37]. The observations made in the zebraﬁsh model system make it
tempting to envisionβ1a as themolecular glue that holds tetrads together
by linking CaV1.1 to RyR1. Interestingly, the possibility of a direct interac-
tion of β1a with a cluster of positively charged amino acids (3495–3502)
in the cytoplasmic amino-terminal region of RyR1 has been raised based
on the in vitro binding of β1a to another fragment of RyR1 (3490–3523)
inclusive of this stretch of residues [41]. In more recent studies, peptides
corresponding to a minimal sequence (residues 490–524) within the
most distal 35 residues of the β1a carboxyl-terminus were found to bind
to native RyR1 in SR vesicles [42,43]. In contrast to these in vitro data
which suggest that β1a can bind to RyR1 independently of CaV1.1,
β1a does not appear to bind to RyR1 in vivo in CaV1.1-null (dysgenic)
myotubes [29,31,44]. These latter data imply that if an association
between β1a and RyR1 occurs in vivo, this association requires the
presence of CaV1.1.
4. CaV1.1 is the voltage sensor for EC coupling
Excitation–contraction (EC) coupling in skeletal muscle requires the
transduction of a plasmalemmal depolarization within the transverse-
tubule network into a transient elevation inmyoplasmic Ca2+ emanatingnormal
EC coupling
L-type current
a b
Fig. 3. Restoration of L-type current and EC coupling in dysgenic (CaV1.1 null) myotubes. EC
currents recorded at +30 mV in the whole-cell conﬁguration (bottom row) from normal m
dysgenic myotubes (right panels). Note the persistence of some T-type Ca2+ current in naïv
Figure modiﬁed from Tanabe et al. [49] with permission from the publisher.from the stores of the sarcoplasmic reticulum (SR) that activates the con-
tractile ﬁlaments [45]. It has been known since the early 1970s that EC
coupling in skeletal muscle does not require the entry of extracellular
Ca2+ [46] but relies on the outward movement of charged, membrane-
bound gating particles [47]. The identity of these voltage-sensing parti-
cles would remain a mystery for another decade, at which point it was
observed that myotubes cultured from a perinatally lethal mouse line
(dysgenic) lacked dihydropyridine-sensitive voltage-gated Ca2+ current
(Fig. 3—middle column) [2]. Around the same time, Ríos and Brum [48]
demonstrated that charge movement and EC coupling were inhibited in
parallel by the dihydropyridine antagonist nifedipine. Together, these in-
dependent works ﬁngered the L-type Ca2+ channel/DHPR as the voltage
sensor. Nearly absolute proof came along a short time later when the
newly cloned CaV1.1 restored L-type current, charge movement and
EC couplingwhen expressed in dysgenicmyotubes (Fig. 3—right column)
[49–52] and today CaV1.1 is universally believed to be the voltage-
sensor for EC coupling in skeletal muscle.
A recent in vivo example underscores the lack of a requirement for
Ca2+ entry via CaV1.1 for skeletal-type EC coupling. Zebraﬁsh have
two distinct CaV1.1 α1S subunit isoforms (α1S-a and α1S-b) that have
both lost the ability over time to conduct L-type current [53]. These
two channels have distinct residue substitutions in the pore helix
that block Ca2+ permeationwhile sparing the ability of both to trigger
EC coupling. Speciﬁcally, α1S-a has a tryptophan–glycine doublet in
place of a methionine–glutamate pair in the P-loop of Repeat I anddysgenic dysgenic + CaV1.1
c
coupling, as indicated by contractions elicited by focal electrical (top row), and Ca2+
yotubes (left panels), naïve dysgenic myotubes (middle panels) and CaV1.1-expressing
e dysgenic myotubes.
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Repeat II. These non-conducting channels are characteristic of higher
teleosts, but the evolutionary pressure driving the non-conducting
amino acid substitutions in zebraﬁsh and other bony ﬁsh [53] remains
a mystery.
The non-channel function of the EC coupling voltage-sensor makes
CaV1.1 truly peculiar among CaV channels since it is the only isoform
capable of efﬁciently coupling membrane depolarization to activation
of an RyR via a Ca2+ entry-independent, conformational coupling
mechanism [51,54,55]. The only other similar phenomenon that has
been described is intracellular Ca2+ release in nerve terminals of the
neurohypophysis, which depends upon an interaction between a
yet-to-be determined CaV1.X channel and RyR1 [56–58]. In any event,
the fairly well-conserved CaV1.2 channel cannot gate RyR1 in cultured
dysgenic myotubes without Ca2+ ﬂowing into the myoplasm through
the channel pore [5,54,55]. The inability of CaV1.2 [51,54,59], CaV2.1
[60], CaV3.2 [61] and the Musca domesticus muscle L-type channel
[62,63] to restore conformational coupling with RyR1 in dysgenic
myotubes enabled the investigation of key elements for EC couplingwith-
in CaV1.1 via chimeric approaches. The studies that utilized CaV1.1-based
chimeras arrived at the conclusion that the II–III linker was a structure
indispensable for skeletal-type EC coupling [51] and, in particular, the
sequence spanning residues 720–764/5 in the center of the linker
were “critical” for this function (Fig. 1) [59,62,64]. Kugler and col-
leagues suggested that residues 744–751 within the critical domain
form a random coil conformation (rather than an α-helix), and that
this random coil enables CaV1.1 to interact with other junctional pro-
teins (e.g., RyR1) upon membrane depolarization [64]. In this study,
Kugler et al. also identiﬁed four amino acids within the critical do-
main (A739, F741, P742, and D744) which they suggested deter for-
mation of the α-helical conformation of the II–III loop that impedes
EC coupling.
The carboxyl-terminal portion of the loop connecting the “critical
domain” to Repeat III, a region which displays substantial sequence
similarity among L-type Ca2+ channels, was later identiﬁed as a key
structure in a study that employed insertion of ﬂuorescent protein
(Fig. 1) [65]. CaV1.1 channels which had YFP introduced at either resi-
due 760 or 785 were incapable of supporting voltage-dependent Ca2+
release from the SR despite somewhat normal channel expression and
the apparent retention of the structural integrity of the critical domain.
At this point, it is not known whether the carboxyl-terminal portion of
the II–III linker is directly involved in gating RyR1 during EC coupling or
whether it is merely a specialized conduit for communication between
the critical domain and the channel's voltage-sensing elements.
Although there is general consensus that the II–III loop is an essen-
tial player in skeletal-type EC coupling, a handful of studies that have
applied synthetic peptide mimics of II–III loop segments to isolated
RyR1 in reconstituted lipid bilayers have produced results which led to
the notion that a segment of the amino-terminal portion of the II–III
loop known as the “A domain” (residues 681–690, minimally; Fig. 1) di-
rectly interacts with, and activates, isolated RyR1 [66–68]. Most recently,
an A domain peptide was found to bind an isolated segment of RyR1, the
ubiquitous SPRY2 domain, and this interaction supported increased Po of
RyR1 in lipid bilayers [69,70]. While provocative, experiments that have
tested the importance of the A domain for EC coupling in a cellular
context have failed time and time again. Speciﬁcally, scrambling or
total ablation of this region has little or no effect on the magnitude
or voltage-dependence of SR Ca2+ release in response to depolarization
[44,65,71–76].
Roles for the other intracellular linkers in EC coupling and/or other
general CaV1.1 functions have also been identiﬁed through deletion or
chimera strategies. The CaV1.1 I–II loop is the site for interaction with
theβ1a subunit,which, as discussed above, supportsmembrane trafﬁck-
ing and is required for the tetradic arrangement of CaV1.1 within triad
junctions (Fig. 2—right). Skeletal-type EC coupling is absent in muscle
cells genetically null for β1a [27,28,30] and is restored by expression ofβ1a and, to a much lesser extent by β2a [37,77], whereas β3 and β4
[78] and theM. domesticus βM [37] are all ineffective.
Based initially on the analysis of deletion mutants and of β1a/β2a
chimeras [77,79], much current attention is focused on the role of
the carboxyl-terminus ofβ1a in EC coupling. A synthetic peptide corre-
sponding to the carboxyl-terminal 35 residues of β1a binds to puriﬁed
RyR1s in vitro and, much like A domain peptides, activates RyR1s in
lipid bilayers [42]. Within this stretch of residues, a hydrophobic heptad
motif unique to β1a was identiﬁed as being an important element for EC
coupling and triple mutation of three of these residues (L478, V485 and
V492) to alanine impaired the ability of rabbitβ1a to support EC coupling
in mouse β1 null myotubes [80]. However, the samemutations were in-
consequential to EC coupling and tetrad formation when expressed in
zebraﬁsh relaxed (β1 null) myotubes [81] and β1a-based peptides with
these substitutions enhanced RyR1 Po to the same extent as peptides
with wild-type sequence [43]. Though the requirement for the
presence of the β1a carboxyl-terminus for the EC coupling is widely
accepted, these diametrically opposed results obtained in divergent
(mammalian vs. osteichthyes and lipid bilayers) systems have given
rise to uncertainty of the role of the hydrophobic heptad repeat in cou-
pling with RyR1.
The inﬂuences of the other intracellular regions of CaV1.1 on EC cou-
pling are not as prominent as that of the I–II and II–III loops. The short
amino-terminus appears largely inert [82]. The III–IV loop is not directly
involved in EC coupling but indirectly can control Ca2+ release from the
SR by inﬂuencingCaV1.1 gating [83]. The III–IV loop also is the only intra-
cellular site on CaV1.1 for mutations linked to the pharmacogenetic dis-
order malignant hyperthermia [84–86]. Finally, the carboxyl-terminus
plays a part in channel expression and targeting of the channel to triad
junctions [60,87] and is the site for many intermolecular interactions
(reviewed in [10]).
5. CaV1.1 channel properties are atypically dependent on
conformational coupling with RyR1
The unique conformational coupling mechanism between CaV1.1
and RyR1 is bidirectional. As described above, the EC coupling, or “or-
thograde,” signal is transduced from the voltage-sensing regions of
CaV1.1 to the pore region of RyR1 via the cytoplasmic foot region of
RyR1 (Fig. 4). The ﬁrst recordings of L-type currents from dyspedic
(RyR1 null) myotubes revealed that there is also an RyR1-mediated
“retrograde” signal that is communicated to the channel-activating
machinery of CaV1.1. In particular, very low amplitude L-type cur-
rents were observed in dyspedic myotubes by Nakai and colleagues
[88], despite nearly normal membrane expression of CaV1.1 inferred
from measurement of charge movements. The reduction in current
density was corrected by exogenous expression of RyR1. Thus, the in-
crease in conductance to charge ratio indicated that the presence of
RyR1 increases CaV1.1 currents by elevating channel relative Po. The
retrograde signal inﬂuences CaV1.1 activation kinetics [89–91] and,
like orthograde coupling, is dependent on the integrity of the critical
domain [92].
Interestingly, RyR1 mutations that alter RyR1 function also affect
certain biophysical properties of CaV1.1. For instance, hyperpolarizing
shifts in channel activation have been consistently observed in animal
models ofmalignant hyperthermia caused by RyR1mutations. Gallant et
al. [93] saw a small hyperpolarizing shift in activation of L-type Ca2+
current in swine myotubes homozygous for the RyR1 R615C mutation,
but speculated that series resistance errors could have been responsible.
A nearly 10 mV hyperpolarizing shift in CaV1.1 activation was also
reported for myotubes obtained from engineered Y522S homozygous
mice [94], as was a small (~3 mV), but signiﬁcant, hyperpolarizing
shift in adult Y522S heterozygous interosseus ﬁbers [95]. Similarly, our
group observed a 7 mV hyperpolarizing shift in L-type current activa-
tion for mouse myotubes homozygous for the engineered R163C muta-
tion [96]. Hyperpolarizing shifts in charge movement have also been
RyR1 null + RyR1
“Retrograde”
ICa enhancing
“Orthograde”
skeletal ECC
Ca2+Ca2+
Ca2+
10 ms
0.
1 
F/
F
50 ms 5
 p
A/
pF
Δ
Fig. 4. Communication between CaV1.1 and RyR1 is bi-directional. The orthograde, or EC coupling, signal is communicated from CaV1.1 to RyR1. This signal is absent from dyspedic
(RyR1 null) myotubes (bottom left). This signal is restored by reintroduction of the SR Ca2+ release channel (bottom right). Interestingly, dyspedic myotubes have meager L-type
Ca2+ current (top left), despite normal CaV1.1 expression. Reintroduction of RyR1 substantially increases L-type current density (top right), indicating that conformational coupling
between CaV1.1 and RyR1 also produces a “retrograde” signal that serves to increase CaV1.1 relative Po.
Figure modiﬁed from Nakai et al. [88] and Grabner et al. [92] with permission from the publishers.
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in swineR165Cmyotubes [97]. In regard to EC coupling, eachof thesema-
lignant hyperthermia models (R163C, Y522S, R615C; [94–96,98,99]) and
dyspedicmyotubes expressing RyR1 constructs carrying a number of dif-
ferentmalignant hyperthermia-linkedmutations [100] has also displayed
hyperpolarizing shifts in SR Ca2+ release in response to depolarization
suggesting that RyR1 malignant hyperthermia mutations shift the equi-
librium of CaV1.1 towards the state(s) active for EC coupling and L-type
channel activation.
6. CaV1.1 displays depolarization-induced shifts into high Po mode
2 gating
CaV1.1 and the other L-type channels have three broadly-deﬁned
gating modes which have been characterized both at macroscopic
and single channel levels [17,101]. Mode 0 represents the closed
state of the channel, mode 1 is characterized by brief (~1 ms) open-
ings and mode 2 displays longer duration openings which are pro-
moted both by exposure to 1,4-dihydropyridine agonists (e.g., (−)
Bay K 8644) and by strong depolarization [101–104]. On the macro-
scopic level, the point of entry into mode 2 is difﬁcult to assess during
depolarizing step potentials and is most evident in the augmented
amplitude and slowed decay of tail currents elicited by repolarization
from steps to more negative potentials [17,105].
7. Does CaV1.1 undergo calcium-dependent inactivation?
Another means in which CaV1.1 differs from other high voltage-
activated CaV channels is its apparent lack of calcium-dependent inac-
tivation (CDI) [106]. This inhibitory feedback mechanism has been
rigorously investigated in CaV1.2, CaV1.3, and CaV2.1 channels and
has been found to require anchoring of calmodulin (CaM) to a con-
served IQ motif in the carboxyl-termini of each of these channels
[107–110]. Even during longer depolarizations that certainly facilitate
substantial Ca2+ entry [15], wild-type CaV1.1 inactivates very little
and what little inactivation there is appears to be dependent on test
potential rather than current amplitude. The lack of CDI for native
L-type channels inmyotubes could be a consequence of factors intrinsicto CaV1.1. For example, introduction of non-conserved CaV1.1 residues
into and near the IQ domain of CaV1.2 ablates both CaM-binding to
the carboxyl-terminus and CDI in HEK293 cells [111]. Interestingly,
CaV1.2 channelswhich normally display considerable CDI in both native
and heterologous systems [see the CDI paper of this series], inactivate
very little when expressed in dysgenicmyotubes [51,54]. This latter ob-
servation suggests that extrinsic factors related to the architecture of
triad junctions could also contribute to the lack of CDI for CaV1.1. It
must be noted that mild CDI has been reported in cultured normal
myotubes [112] and adult mouse ﬂexor digitorum brevis (FDB) ﬁbers
[113]. Thus, the topic of whether CaV1.1 is prone to CDI merits further
investigation in light of these latter results.
8. Excitation-coupled Ca2+ entry and CaV1.1
Over many years, the extremely slow activation of the skeletal
muscle L-type Ca2+ current has cast doubt on whether CaV1.1 can
actually mediate signiﬁcant Ca2+ entry into muscle ﬁbers during
the short duration (~5 ms) of a tubular action potential. The discovery
of excitation-coupled Ca2+ entry (ECCE) by Cherednichenko and col-
leagues [114] has sparked new interest in this topic. ECCE was initially
described as a large, slowly developing mode of Ca2+ entry into skeletal
muscle that occurs in response to either repetitive or prolonged mem-
brane depolarization [26,114–119]. Such Ca2+ entry was detected in
both cultured myotubes and adult muscle ﬁbers, either as Ca2+ tran-
sients in the presence of ryanodine or asMn2+ quench of the ratiometric
Ca2+ indicator Fura-2 [26,114,115,117,118]. ECCE has also been assessed
indirectly in cells in which SR Ca2+ release has not been blocked by
ryanodine as the difference between the Ca2+ transients measured in
the presence and absence of external Ca2+ [15,116,119]. Interestingly,
ECCE was absent in myotubes that are null for either RyR1 or CaV1.1
α1S or β1a subunits [15,16,114,115,118]. It was also sensitive to block by
dihydropyridine antagonists, large di- and tri-valent cations and other
widely used non-selective cation channel blockers such as SKF-96356
and 2-aminoethyl diphenylborate (2-APB) [15,114,116]. At ﬁrst glance,
the ablation of ECCE in these cases would have pointed directly to the
L-type channel as the mediator of ECCE. Even so, Cherednichenko et al.
[114] proposed that ECCE is independent of L-type Ca2+ current via the
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persisted in dysgenic myotubes transfected with an CaV1.1 pore mutant
(SkEIIIK) thought to conduct only outwardmonovalent ﬂux [5]. The per-
sistence of ECCE in SkEIIIK-expressing dysgenicmyotubes led to the idea
that another Ca2+-permeable channelwhose gatingwas coupled directly
to the intact CaV1.1–RyR1 complex was responsible for conducting the
Ca2+ entry attributed to ECCE.
Initial investigations of the molecular basis of ECCE focused on
TRPC3 channels which are abundantly expressed in skeletal muscle
[120] and Orai1/STIM1 complexes responsible for store-operated
Ca2+ entry in skeletal muscle [118,121,122]. For both, ECCE seemed
to be unaffected by siRNA or dominant-negative constructs targeting
either channel type [118,123]. The lack of contribution from either of
these channels prompted a re-examination of the CaV1.1 pore as the
ECCE pathway. Indeed, the native L-type channel conducted Mn2+
and supported ECCE-like Ca2+ entry during long, weak depolarizations.
Moreover, ECCE was substantially reduced in dysgenic myotubes ex-
pressing SkEIIIK in comparison to normal myotubes [15]. Thus, the ma-
jority of Ca2+ entry attributed to ECCE seemed actually to ﬂow through
CaV1.1. Still, the lack of Ca2+ entry observed in dysgenic myotubes ex-
pressing SkEIIIK by Bannister et al. [15] contrasted on the surface with
the robust Mn2+ quench originally observed by Cherednichenko et al.
[114]. These results were reconciled by the fact that SkEIIIK does
become permeable to Ca2+ or Mn2+ when it enters mode 2 gating
as it would during long, weak depolarization by elevated K+ or during
repetitive electrical stimulation [15,16].
Even though the molecular identity of the permeation pathway
remains a matter of some debate [3,4], the voltage-sensor for activa-
tion of ECCE is by deﬁnition housed in CaV1.1. For this reason, any
physiological impact of ECCE is directly controlled by CaV1.1. In the
original characterization of ECCE, Cherednichenko et al. [114] showed
that the rate of Mn2+ quench increases with frequency of electrical
ﬁeld stimulation. During continuous application of tetanic stimuli,
Ca2+ entrywith similar pharmacology to ECCE has been shown tomain-
tain myoplasmic Ca2+ levels, suggesting that such dihydropyridine-
sensitive Ca2+ ﬂux may play a role in store replenishment during vigor-
ous activity.
9. Mutations in CaV1.1 are directly linked to pathophysiological
alterations of muscle
Mutations in CaV1.1 have been identiﬁed as causative for two con-
genital muscle pathophysiologies, hypokalemic periodic paralysis
(HypoKPP) [124,125] and malignant hyperthermia [126,127]. CaV1.1
was ﬁrst identiﬁed as being a locus for HypoKPP by Ptáček and col-
leagues in 1994 [128]. A PCR-based investigation revealed multiple
probands with mutations resulting in H/G substitutions for R1239,
the second basic residue in the voltage-sensing S4 helix of Repeat IV.
At least fourteen other HypoKPP mutations of charged residues in the
voltage sensing helices of CaV1.1 (R528H, R900H and R1239H; Fig. 1)
and the skeletal muscle Na+ channel (NaV1.4) have been identiﬁed
since [129–131]. Curiously, the mild effects which these alterations of
the putative voltage-sensing structures of CaV1.1 and NaV1.4 have on ei-
ther channel's conventional biophysical characteristics could not explain
the onset of a HypoKPP episode satisfactorily [131–139]. For example,
electrophysiological analysis of myotubes derived frommuscle biopsies
of affected individuals carrying the CaV1.1 Repeat II S4 R528H mutation
revealed only a small reduction in current density and slowed activation
kinetics [135]. Subsequent work on HypoKPP-linked NaV1.4 mutants
revealed the mechanism of channel dysfunction in HypoKPP to be the
creation of a transmembrane “gating pore” that conducts protons through
the channel via a route other than the classic ionic permeation via the
central pore [140–142]. The presence of zwitterionic histidines at the
second conserved basic residue position of NaV1.4 voltage-sensing
helices enables proton ﬂux when the voltage sensors are in the resting
position, thereby enabling the passage of the smallest of monovalentcations into the intracellular space. Electrophysiological analysis of
mouse FDB ﬁbers in which the human ortholog (NaV1.4 R669H) had
been introduced genetically demonstrated that resultant inward
ω-current conducted by the gating pore is the basis for muscle ﬁber
depolarization when external K+ is reduced and is therefore sufﬁcient
to trigger a HypoKPP episode [143]. It is thought that mutations in
CaV1.1 S4 helices such as R528H also cause HypoKPP episodes by
conducting ω-current in the same manner as NaV1.4 mutants [131]. If
this is the case, the dysfunction of CaV1.1 that causes HypoKPP episodes
is unrelated to its ability to function as either voltage-sensor for EC cou-
pling or as an L-type Ca2+ channel.
In addition to the >120 known causative mutations for malignant
hyperthermia in RyR1 [144], ﬁve mutations have been identiﬁed in
CaV1.1 [84–86,145,146]. These ﬁve missense mutations encode the
following substitutions: 1) R174W, 2) T1354S, 3) R1086H, 4) R1086C,
and5) R1086S (Fig. 1). Of these, the R174W, R1086H andT1354S substi-
tutions have been functionally characterized [146–148]. In each case,
the mutations had only subtle effects on the ability of CaV1.1 to trigger
Ca2+ release from the SR in response to depolarization. In regard to
the effects of the mutations on the ability of the channel to conduct
L-type Ca2+ current, the primary effects of R1086H and T1354S muta-
tions were lowered relative Po and accelerated channel activation,
respectively [146,147]. The impact of the R174W mutation on L-type
current was much more severe than R1086H or T1354S, as it abolished
channel activation in response to 200 ms depolarizations [148].
Taken together, the minor effects on EC coupling and the varied
functional consequences on the L-type current raise many questions
regarding the causative role for CaV1.1 mutations in malignant hyper-
thermia susceptibility. Recently, it has been proposed that altered
resting coupling between mutant CaV1.1 and RyR1 may underlie ma-
lignant hyperthermia susceptibility. The basis for this proposal is that
resting myoplasmic Ca2+ levels of dysgenic myotubes lacking CaV1.1
are elevated to levels reminiscent of those in muscle of malignant hy-
perthermia mouse models and in dyspedic myotubes expressing mu-
tant RyR1s [149–151]. The increased resting Ca2+ levels observed in
dysgenic myotubes were rectiﬁed by expression of CaV1.1 [151] but
persisted when the CaV1.1 R174W mutant was introduced into these
cells instead [148]. Since the R174W mutation had little effect on EC
coupling and abolished channel function, it was proposed that altered
resting coupling between CaV1.1 and RyR1 promotes a ryanodine-
insensitive, RyR1-mediated SR Ca2+ leak pathway [152] that leads to
elevated myoplasmic Ca2+ levels and hypersensitivity to halogenated
anesthetics in CaV1.1 R174W-expressing dysgenicmyotubes.
10. Reduced CaV1.1 expression contributes to aging-related
strength deﬁcits
Muscle weakness in older individuals is partially attributable to
depressed muscle excitability—a process termed “EC uncoupling.”
Previous studies have shown that EC uncoupling in both human and ro-
dentmuscle is characterized by decreased voltage-triggered SR Ca2+ re-
lease [153,154]. Concurrent reductions in L-type current amplitude and
maximal intramembrane charge movement indicate that reduced SR
Ca2+ release in older mammals is a consequence of reduced number
of EC coupling voltage-sensors (i.e., CaV1.1 channels) resident in the
plasmamembrane of the transverse tubule network. This idea is further
supported by a reduction in radioactive dihydropyridine binding in
musclemembrane preparations fromolder rats [155]. Although a reduc-
tion inmembrane expression of CaV1.1 has been established as the basis
of age-related EC uncoupling [156], the molecular signals that drive this
process remain unclear.
Interestingly, Piétri-Rouxel [157] recently demonstrated that expres-
sion of CaV1.1 is required for maintaining muscle integrity. In this study,
mouse hindlimb muscle that had been infected with siRNA directed to
CaV1.1 had gross atrophy, reduced ﬁber diameter and substantially
moreﬁbrosis than the control contralateralmuscle. Although the authors
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Fig. 5. A high-conductance CaV1.1 splice variant expressed in developing skeletal muscle. L-type currents recorded from dysgenic myotubes expressing either an adult α1S isoform
(CaV1.1a) [1] or an embryonic α1S isoform lacking exon 29 [158] are shown in (A—left). A comparison of I–V relationships shows that CaV1.1e has considerably larger current den-
sity and a hyperpolarizing shift in the voltage-dependence of activation relative to CaV1.1a (A—right). Myoplasmic Ca2+ transients are augmented for CaV1.1e (B—left), but the in-
crease and hyperpolarizing shift in Fluo-4 signal represent the contribution of the L-type current because the ΔF/F–V relationship is nearly identical when Ca2+ entry via CaV1.1 is
blocked by Cd2+ and La3+ (B—right).
Figure modiﬁed from Tuluc et al. [158] with permission of the publishers; © Elsevier, 2009.
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CaV1.1 ablation were a consequence of loss of EC coupling, L-type cur-
rent, and/or downstream use-dependent contractile activity, their ﬁnd-
ings raise the possibility that CaV1.1 activity is involved in maintaining
muscle mass.
11. Developing and differentiated muscle expresses different CaV1.1
splice variants
The idea that CaV1.1 could support substantial Ca2+ entry in
myotubes was bolstered by the discovery of a high conductance
embryonic/neonatal splice variant of CaV1.1 [158]. The newly de-
scribed CaV1.1e variant is missing exon 29, which encodes 19 residues
within the short segment connecting helices S3 and S4 of the fourth
conserved repeat (Fig. 1). qRT-PCR analysis of CaV1.1 transcript levels
revealed that CaV1.1e comprises nearly 80% of CaV1.1 expressed in
wild-type myotubes. Although CaV1.1e was able to engage EC coupling
with similar efﬁciency as the original variant cloned from adult muscle
(CaV1.1a) [1], L-type Ca2+ currents conducted by CaV1.1e displayed
very different properties (Fig. 5). Since CaV1.1e activated at signiﬁcantly
more hyperpolarizing potentials and had an augmented Po, the current
was more than seven times larger than the CaV1.1a variant. Block of
Ca2+ entry with Cd2+ and La3+ also revealed a large component ofCa2+ transient that is a consequence of the current conducted by
CaV1.1e. The ﬁndings of Tuluc et al. [158] not only explainedwhy native
L-type currents in myotubes are different in voltage-dependence and
amplitude from dysgenicmyotubes expressing adult rabbit CaV1.1 chan-
nels, but also demonstrated that native L-type currents inmyotubes are
capable of supporting robust Ca2+ entry [159].
Even before the absence of L-type current in dysgenic muscle was
established [2], itwas known that thediaphragmsof dysgenicmicehad al-
tered innervation. In particular, dysgenic diaphragms display dispersed
acetylcholine receptor (AChR) clusters rather than the central band of
clusters present in diaphragm of normal mouse embryos [160–162].
Similarly, the diaphragmsofβ1 null embryos display dispersedAChR clus-
ters, and increased expression of both MuSK, an established promoter of
AChR clustering, and AChRs [163]. Accompanying the changes in muscle,
there is extensive sprouting of motor axons in both dysgenic [161] and β1
null mice [163], whereas motor axons terminate at the central band of
AChRs in wild-type mice. The muscle-speciﬁc re-introduction of β1a
(a transgenic technology thatwas unavailable in early characterizations
of the dysgenic line) restores centrally located AChR clusters and, as a
consequence, also eliminates the extensive nerve branching.
One common defect in these two effectively CaV1.1 null mouse
models appears to be Ca2+ inﬂux via CaV1.1. In particular, treatment of
C2C12 cells with the L-type channel antagonists isradipine and verapamil
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with the L-type channel agonist (−)Bay K 8644 reduced the levels of
both transcripts [163]. Interestingly, earlierworkusing a similar approach
on culturedmuscle cells had shown that the activity-dependent stabiliza-
tion of AChRs at the endplate is dependent on L-type Ca2+ entry [164].
Taken together, these results provide support for the idea that the large
Ca2+ currents produced by the embryonic/neonatal CaV1.1e splice
variant [158] may be important for normal embryonic and neonatal
development [165].
Ca2+ inﬂux via the CaV1.1e variantmay contribute to the pathology of
muscle in the multi-organ disorder, myotonic dystrophy type 1 (DM1).
DM1 patients exhibit the re-emergence of the embryonic CaV1.1e variant
as a result of altered activity of the splice factors, MBNL1 and CUGBP1
[166]. Moreover, normal adult mouse FDB ﬁbers expressingmorpholinos
designed to promote skipping of exon 29 showed an increase in peak
density, and hyperpolarizing shift in activation, of L-type Ca2+ current
which are consistent with the behavior of CaV1.1e expressed in dysgenic
myotubes. The morpholino-treated FDB ﬁbers also displayed enhanced
voltage-evoked myoplasmic Ca2+ transients, which were shown by the
addition of Cd2+ and La3+ to the external medium to contain a signiﬁ-
cant contribution from the L-type Ca2+ current. Thus increased entry of
Ca2+ via CaV1.1e represents a possible contributor to the dystrophic
phenotype of DM1, an ideawhich is supported by the increased presence
of central nuclei in tibialis anterior muscle of adult mice expressing
CaV1.1e [166].
12. Summary
The unique capability of CaV1.1 to serve as the voltage sensor for
EC coupling has long overshadowed its more traditional ability to
conduct L-type Ca2+ current. However, the recent work indicating
that Ca2+ does indeed enter muscle cells during depolarization
through a dihydropyridine-sensitive pathway has given rise to a
new curiosity about CaV1.1 as a Ca2+ channel. In this regard, the emer-
gence of the high-conductance CaV1.1e splice variant has demonstrated
that Ca2+ ﬂux though the L-type channel can be rapid, substantial and
physiologically relevant. Moreover, the reappearance of this embryonic
variant in the muscle of DM1 patients has shown that L-type Ca2+
entry certainly has pathological consequences.
Even though interest in CaV1.1 as the channel has undergone a re-
naissance, the atypical role of EC coupling voltage sensor still commands
more experimental attention, as it underlies an essential and conserved
biological function. While there is consensus among investigators that
the α1S II–III loop and the β1a subunit make indispensable contributions
to EC coupling, the precise role(s) of these components of CaV1.1 remain
enigmatic. In addition, the conformational changes that occur in the
membrane-bound portions of the channel upon depolarization have
not yet been characterized and how these molecular rearrangements
are transduced to RyR1 to engage Ca2+ efﬂux from the SR is even more
of a conundrum. Taken together, the investigation of these dual functions
of the prototypical, yetmost atypical, CaV channelwill assuredly fascinate
and frustrate muscle biologists for some time to come.
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